12-1239-42

antibody from Invitrogen Antibodies

Targeting: IL3RA CD123

Provider product page for 12-1239-42

Flow cytometry

Other assay

Antibody data

Antibody Data
Antigen structure
References [24]
Comments [0]
Validations
Flow cytometry [1]
Other assay [4]

Submit

Product number: 12-1239-42 - Provider product page
Provider: Invitrogen Antibodies
Product name: CD123 Monoclonal Antibody (6H6), PE, eBioscience™
Antibody type: Monoclonal
Antigen: Other
Description: Description: The 6H6 monoclonal antibody reacts with human CD123, the alpha chain of the IL-3 receptor. This 60-70 kDa transmembrane protein binds to IL-3 with low affinity by itself, and when associated with CD131 (common beta chain) binds IL-3 with high affinity. CD123 is expressed by myeloid precursors, macrophages, dendritic cells, mast cells, basophils, and megakaryocytes. Applications Reported: The 6H6 antibody has been reported for use in flow cytometric analysis. Applications Tested: This 6H6 antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells. This can be used at 5 µL (0.25 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. Excitation: 488-561 nm; Emission: 578 nm; Laser: Blue Laser, Green Laser, Yellow-Green Laser. Filtration: 0.2 µm post-manufacturing filtered.
Reactivity: Human
Host: Mouse
Conjugate: Yellow dye
Isotype: IgG
Antibody clone number: 6H6
Vial size: 100 Tests
Concentration: 5 µL/Test
Storage: 4° C, store in dark, DO NOT FREEZE!

IL3RA protein structure - 12-1239-42 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL
Conjugate: Yellow dye

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL
Conjugate: Yellow dye

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 5 Identification of multiple mDC and pDC subsets by MegaClust. (A) Comparison of the different clusters identified by MegaClust as mDCs and pDCs (example for one patient for four time points). (B) Expression level of CD123 and CD11c of the two mDC clusters and the two pDC clusters identified by MegaClust. (C) Expression levels of HLA-DR and CD4 for the two pDC clusters and the two mDC clusters identified by MegaClust. Cluster 53 could be assigned as basophils due to the lack of expression of CD4 and HLA-DR (). The expression of CD4 is shown for CD4 T cells and CD14 + monocyte clusters for comparison. (D) Overlay of CD4 and HLA-DR of MegaClust identified clusters for mDC, pDC, basophils, CD4 and monocytes. (E) mDCs and pDCs were discriminated according to CD11c and CD123 expression in the supervised flow cytometry re-analysis according to the new gating strategy described in Supplementary Figure 5 (one representative patient 0QZW). (F) Representative illustration of HLA-DR and CD4 co-expression on mDCs and pDCs prior to FACS sorting CD11c+CD123 - CD4 + HLA-DR+ mDCs and CD123 + CD11c - CD4 + HLA-DR + were FACS sorted (dotted lines). (G) Gene expression profiles of flow cytometry sorted CD11c + CD123 - CD4 + HLA-DR + mDCs, CD123 + CD11c - CD4 + HLA-DR + CD4 + HLA-DR + pDC and CD14 + CD16 - monocytes from 3 healthy donors are shown in comparison to the RNA expression profile of public available RNAseq datasets (Immgen) indicating the gene expression profile of B cells, mac
Conjugate: Yellow dye

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 (A) Surface antigen expression of bone marrow stromal cells (BMSCs) isolated from the talus bone marrow using flow cytometry. >95% of cells were negative for CD45 and CD14, and >99% of cells were negative for CD19 and CD34. In addition, >95% were positive for CD73, CD90, CD105, and CD140b. Since plastic adherence is a well-established and validated technique to isolate multipotent stromal cells (MSCs), we have only characterized one BMSC donor using flowcytometry instead of all donors. The blue lines are stained cells and the gray lines are negative (unstained) controls. Adapted from Croes et al. ( 25 ). (B) Fluorescence-activated cell sorting (FACS) gating strategy used to isolate granulocytes/neutrophils from peripheral blood leukocytes. Granulocytes were either isolated from unlabeled leukocytes using gate 1 (G1) within the forward/sideward scatter (FSC/SSC). Alternatively, leukocytes were stained using CD3, CD14, CD193, and CD123. Within the FSC/SSC of these labeled cells, debris was first excluded [gate 2 (G2)]. Subsequently, CD3+ cells (lymphocytes) and CD14+ (monocytes) were excluded [gate 3 (G3)]. In addition, CD193+ cells (eosinophils) and CD123+ cells (basophils) were excluded [gate 4 (G4)]. The remaining CD3- CD14- CD193- CD123- cells were defined FACS-sorted neutrophils (G2+, G3+, G4+ sorted neutrophils). Re-analysis of FACS-sorted neutrophils shows adequate exclusion of lymphocytes and monocytes based on their FSC/SSC. (C) Images of BMSCs obtained by arr
Conjugate: Yellow dye